In a 76‑year‑old female undergoing chemotherapy who is taking escitalopram (Lexapro) 20 mg daily and has stopped crying spells but appears withdrawn, should the escitalopram dose be increased or should an additional medication be added?

Do Not Increase Lexapro or Add Medication at This Time

The patient's withdrawn behavior is not necessarily inadequate antidepressant response—it may reflect appropriate grief, existential distress, or physical symptoms from cancer/chemotherapy that require different interventions than dose escalation. Before making any medication changes, you must first distinguish between treatment-resistant depression versus normal adjustment to serious illness, chemotherapy side effects (fatigue, cognitive changes), or unaddressed physical symptoms.

Critical Assessment Before Any Medication Change

The statement "look at me" suggests the patient may be experiencing:

• Appropriate grief/existential distress about her cancer diagnosis and treatment
• Chemotherapy-related fatigue or cognitive changes (extremely common and often mistaken for depression)
• Physical symptom burden (pain, nausea, sleep disturbance) that mimics or worsens mood symptoms
• True treatment-resistant depression

You cannot distinguish these without targeted assessment:

Immediate Evaluation Required:

• Physical symptom control: Is pain adequately managed? Sleep quality? Chemotherapy side effects controlled? 1
• Functional status: Can she perform activities of daily living? Is withdrawal from fatigue versus anhedonia?
• Cognitive function: Chemotherapy-induced cognitive changes are common and can present as withdrawal 2
• Suicidal ideation: Any passive death wishes or active suicidal thoughts? 3
• Duration of current symptoms: Crying stopped (positive response) but when did withdrawal begin?

Why Not to Increase Lexapro Now

The FDA label indicates 10-20 mg are both effective for depression, with trials failing to demonstrate greater benefit of 20 mg over 10 mg 3. She's already at the maximum standard dose of 20 mg.

Research shows:

• Higher doses (above 20 mg) carry increased risks: One study found tolerability declined above 40 mg, with 26% unable to tolerate 50 mg 4
• Dose-related adverse effects: Treatment-emergent mania/hypomania can occur with dose increases to 20 mg 5
• Discontinuation syndrome risk increases with higher doses and plasma concentrations 6

In elderly patients (she's 76), escitalopram 10 mg daily is the recommended dose due to altered pharmacokinetics 3. She's already receiving double this dose.

Alternative Management Strategy

First-Line: Address Non-Pharmacologic Factors

Before any medication change:

1. Optimize physical symptom management 1:

   • Review antiemetic regimen if nausea present
   • Assess pain control
   • Evaluate sleep (consider gabapentin 300-900 mg at night if sleep-disturbed) 7

2. Offer psychological intervention (evidence-based for cancer patients with depression) 8:

   • Cognitive behavioral therapy (CBT) - strongest evidence
   • Behavioral activation (BA)
   • Supportive psychotherapy - specifically studied in cancer patients 2
   • These interventions address existential distress that medication cannot

3. Assess for chemotherapy-related cognitive changes 2:

   • Memory and Attention Adaptation Training (MAAT) has shown benefit
   • Psychostimulants (methylphenidate, modafinil) may help if cognitive dysfunction confirmed

If Medication Change Truly Needed

Only after ruling out above factors and if clear treatment-resistant depression:

Consider augmentation rather than dose increase 8, 9:

• Add psychotherapy (combined CBT + medication superior to either alone for partial responders) 8
• Consider methylphenidate as augmentation (shown effective in terminally ill cancer patients, though increased nervous system adverse events) 8
• Avoid benzodiazepines long-term despite anxiety - increased cognitive impairment risk in elderly 9

Do NOT simply increase escitalopram above 20 mg - no evidence of benefit, increased harm risk in elderly patient.

Common Pitfalls to Avoid

• Mistaking chemotherapy fatigue for depression: Physical exhaustion presents as withdrawal but doesn't respond to antidepressant dose increases
• Ignoring existential distress: "Look at me" suggests grief about physical changes - this requires psychological support, not medication escalation
• Polypharmacy in elderly: She's 76 and on chemotherapy - drug interactions and adverse effects multiply
• Assuming partial response = need for higher dose: Crying stopped (positive response) but withdrawal may be separate issue

Recommended Action Plan

1. Meet with patient privately to explore "look at me" comment - assess for grief, body image concerns, existential distress
2. Review symptom burden systematically - pain, fatigue, sleep, nausea, cognitive function
3. Refer for psycho-oncology consultation or supportive psychotherapy 2, 8
4. Optimize physical symptom management before medication changes 1
5. Continue current Lexapro 20 mg - she has had partial response (crying stopped)
6. Reassess in 2-4 weeks after addressing above factors

Only escalate pharmacotherapy if clear treatment-resistant depression persists after optimizing supportive care and addressing physical symptoms.